Medicine information TALIDOMIDA BMS 50mg capsules

Product code:
W68371001
Quantity:
28
Indicated for:
cancer
Route of administration:
oral
Substance:
thalidomide (immunomodulator)
ATC
L04AX02 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Other immunosuppressants
Thalidomide is a medication currently used to treat certain conditions such as multiple myeloma, erythema nodosum leprosum (a complication of leprosy), and other inflammatory or autoimmune diseases. It is known for its immunomodulatory, anti-inflammatory, and antiangiogenic properties, making it useful in controlling inflammation and tumor growth.

How it works: Thalidomide inhibits the production of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), and reduces the formation of new blood vessels (angiogenesis), which limits tumor growth.

Main indications:

- Multiple myeloma: Used in combination with other drugs to slow disease progression.
- Erythema nodosum leprosum: Helps reduce inflammation and associated symptoms.
- Autoimmune diseases: In some cases, it is used off-label for conditions like systemic lupus erythematosus or Crohn's disease.

Side effects: Thalidomide may cause drowsiness, constipation, peripheral neuropathy (numbness or tingling in the hands and feet), dizziness, and skin rashes. In rare cases, it can increase the risk of blood clots.

Special warnings: Thalidomide is highly teratogenic, meaning it can cause severe birth defects if taken during pregnancy. For this reason, its use is strictly regulated, and women of childbearing age must follow strict contraceptive measures.

General data about TALIDOMIDA BMS 50mg

Substance:
thalidomide
Date of latest medicines list:
01-10-2026
Product code:
W68371001
Strength:
50mg
Pharmaceutical form:
capsules
Quantity:
28
Product type:
Original
Price:
1431.44 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
CELGENE DISTRIBUTION B.V. - OLANDA
Holder:
BRISTOL-MYERS SQUIBB PHARMA EEIG - IRLANDA
Number:
443/2008/01
Shelf life:
5 years

Official documents

The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.

Added to database:
01/12/2009
Source record updated:
22/01/2025

Warnings:

Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Avoid live vaccines

Avoid live vaccines during treatment if contraindicated.

Immunosuppression / infection risk

This medicine may increase the risk of infections.

Teratogenic / fetal risk

This medicine may affect fetal development.

Reimbursement lists for TALIDOMIDA BMS 50mg Bristol Myers Squibb

NHP 3 (C2) - NHP oncology

Price
1431.44 RON
Copayment
1431.44 RON
Patient payment
0.00 RON